H.C. Wainwright Assumes Ultragenyx Pharma (RARE) at Buy, PT $82, 'Steep Discount Heading Into a Catalyst-Rich 2023'
Tweet Send to a Friend
(Updated - December 30, 2022 6:04 AM EST)
H.C. Wainwright analyst Ed Arce assumes coverage on Ultragenyx Pharma (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
H.C. Wainwright analyst Ed Arce assumes coverage on Ultragenyx Pharma (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
